Marrow Therapeutics Overview

  • Status
  • Private

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $120M

  • Investors
  • 11

Marrow Therapeutics General Information

Description

Developer of precision genetic medicines designed to treat severe blood disorders through targeted delivery. The company utilizes validated antibody-based therapeutics to specifically target cells affected by conditions like sickle cell disease and beta thalassemia early in their development, enabling the potential for functional cures without the need for traditional, invasive procedures.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 100 Forge Road
  • Suite 200
  • Watertown, MA 02472
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Drug Delivery
Vertical(s)
Corporate Office
  • 100 Forge Road
  • Suite 200
  • Watertown, MA 02472
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Marrow Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series B) 17-Nov-2026 $120M Completed Clinical Trials - General
2. Early Stage VC (Series A) Completed Clinical Trials - General
1. Seed Round $2M $2M Completed Clinical Trials - General
To view Marrow Therapeutics’s complete valuation and funding history, request access »

Marrow Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
Series A-1
Seed 2,075,001 $0.000100 8% $1 $1 1x $1 9.74%
To view Marrow Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Marrow Therapeutics Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Affinity Asset Advisors Hedge Fund Minority
Columbia Threadneedle Investments Asset Manager Minority
Kohlberg Kravis Roberts PE/Buyout Minority
NextBio Capital Venture Capital Minority
Opaleye Hedge Fund Minority
You’re viewing 5 of 11 investors. Get the full list »

Marrow Therapeutics FAQs

  • Where is Marrow Therapeutics headquartered?

    Marrow Therapeutics is headquartered in Watertown, MA.

  • What industry is Marrow Therapeutics in?

    Marrow Therapeutics’s primary industry is Drug Discovery.

  • Is Marrow Therapeutics a private or public company?

    Marrow Therapeutics is a Private company.

  • What is Marrow Therapeutics’s current revenue?

    The current revenue for Marrow Therapeutics is .

  • How much funding has Marrow Therapeutics raised over time?

    Marrow Therapeutics has raised $175M.

  • Who are Marrow Therapeutics’s investors?

    Affinity Asset Advisors, Columbia Threadneedle Investments, Kohlberg Kravis Roberts, NextBio Capital, and Opaleye are 5 of 11 investors who have invested in Marrow Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process